triumph-1 retatrutide trial results: Retatrutide, the triple agonist. Significant weight loss ( 28.3% average loss at 80 weeks). It has potential to transform obesity treatment with results comparable to… Retatrutide Phase 3: TRIUMPH Program

Ethics declarations Ethics approval and consent to participate The current study was approved by the Research Ethics Committee of Isfahan University of Medical Sciences (ID: IR.MUI.RESEARCH.REC.1400.037, March 2021)

Results were that incidence of biliary disease, i.e., conditions that effect the gallbladder/bile ducts, (per 1,000 person-years) was 11.7 for semaglutide, 18.6 for liraglutide (another GLP-1 agonist), and 12.6 for bupropion-naltrexone and 4.6, 7.9 and 1.0, respectively, for pancreatitis

It does so by blocking the enzyme that triggers melanin production in the skin

In this retrospective cohort study, adults (1889 years) undergoing outpatient esophagogastroduodenoscopy or colonoscopy within the HCA Healthcare network from 1 July 2021 to 31 March 2024 were identified

Additionally, patient preference for medications with dual benefits of glucose control and weight management is strengthening demand for GLP-1 therapies across global healthcare systems